Study aims and goal: Phase III study to investigate the efficacy, safety and tolerability of Votoplam in participants with Huntington’s Disease.
No. of study participants and sites: It is planned to enrol 770 participants globally. The number of sites and countries is still to be determined.
For further information see the clinical trial registration.

*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]